|
|
|
|
|
|
|
|
|
|
|
|
|
14.11.25 - 08:18
|
PRESS RELEASE: CMB.TECH announces Q3 2025 results on 26/11/2025 (GlobeNewswire EN)
|
|
|
Antwerp, Nov. 14, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its third quarter 2025 earnings prior to market opening on Wednesday 26 November 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page....
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxanide (NTZ). GENFIT is advancing NTZ through a novel formulation, investigational drug G1090N, which serves as the cornerstone of our ACLF pipeline and reflects our commitment to addressing critical unmet needs in liver disease. G1090N was designed to optimize dose-response and permit sufficient dosing flexibility in patients with ACLF, who are known to have varying degrees of renal or hepatic impairment or failure....
|
|
|
|
|
|
|
07.11.25 - 09:30
|
Euronext CEO on Pan-European Exchange, Buyback (Bloomberg)
|
|
|
Euronext CEO said he'd have interest in Deutsche Boerse if it was willing to sell, in a response to German Chancellor Merz's call for the creation of a pan-European exchange. Earlier this year, Stephane Boujnah had said he would be open to buying the London stock exchange.
This comes as Euronext launched a 250 million euro share buyback after third-quarter profit beat expectations.
Stephane Boujnah spoke with Bloomberg's Kriti Gupta and Guy Johnson from Rome. (Source: Bloomberg)...
|
|
|
07.11.25 - 01:42
|
Euronext N.V. Bottom Line Falls In Q3 (AFX)
|
|
|
PARIS (dpa-AFX) - Euronext N.V. (ENX.PA) announced a profit for third quarter that Drops, from last yearThe company's earnings totaled EUR149.7 million, or EUR1.49 per share. This compares with EU......
|
|
|
|
|
06.11.25 - 18:42
|
Euronext Q3 Profit Down (AFX)
|
|
|
PARIS (dpa-AFX) - Euronext N.V. (ENXB.BE, ENX.BR, ENX.AS, ENX.PA), a pan-European bourse, on Thursday reported third-quarter net income of 149.7 million euros or 1.49 euros per share, compared to ......
|
|
|
|
|
|
|
|
|
05.11.25 - 22:03
|
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & Nasdaq: GLPG) today announced its financial results for the first nine months of 2025, and provided a third quarter and recent business update. “We successfully delivered on our commitment to define a clear path forward for Galapagos following the completion of the strategic review of our cell therapy business,” said Henry Gosebruch, CEO of Galapagos. “We have built a te...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
